Your browser doesn't support javascript.
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.
Milic, Jovana; Novella, Alessio; Meschiari, Marianna; Menozzi, Marianna; Santoro, Antonella; Bedini, Andrea; Cuomo, Gianluca; Franceschini, Erica; Digaetano, Margherita; Carli, Federica; Ciusa, Giacomo; Volpi, Sara; Bacca, Erica; Franceschi, Giacomo; Yaacoub, Dina; Rogati, Carlotta; Tutone, Marco; Burastero, Giulia; Faltoni, Matteo; Iadisernia, Vittorio; Dolci, Giovanni; Cossarizza, Andrea; Mussini, Cristina; Pasina, Luca; Guaraldi, Giovanni.
  • Milic J; Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Novella A; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
  • Meschiari M; Pharmacotherapy and Appropriateness of Drug Prescription Unit, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Menozzi M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Santoro A; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Bedini A; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Cuomo G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Franceschini E; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Digaetano M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Carli F; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Ciusa G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Volpi S; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Bacca E; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Franceschi G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Yaacoub D; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Rogati C; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Tutone M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Burastero G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Faltoni M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Iadisernia V; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Dolci G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Cossarizza A; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Mussini C; Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
  • Pasina L; Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Guaraldi G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
AIDS Res Hum Retroviruses ; 37(4): 283-291, 2021 04.
Article in English | MEDLINE | ID: covidwho-1207222
Semantic information from SemMedBD (by NLM)
1. Negative PROCESS_OF Patients
Subject
Negative
Predicate
PROCESS_OF
Object
Patients
2. cobicistat / darunavir TREATS Negative
Subject
cobicistat / darunavir
Predicate
TREATS
Object
Negative
3. cobicistat / darunavir TREATS Pneumonia caused by SARS-CoV-2
Subject
cobicistat / darunavir
Predicate
TREATS
Object
Pneumonia caused by SARS-CoV-2
4. Pneumonia caused by SARS-CoV-2 PROCESS_OF Patients
Subject
Pneumonia caused by SARS-CoV-2
Predicate
PROCESS_OF
Object
Patients
5. cobicistat / darunavir TREATS Patients
Subject
cobicistat / darunavir
Predicate
TREATS
Object
Patients
6. Cessation of life PROCESS_OF Patients
Subject
Cessation of life
Predicate
PROCESS_OF
Object
Patients
7. Drug Interactions PROCESS_OF Patients
Subject
Drug Interactions
Predicate
PROCESS_OF
Object
Patients
8. Negative PROCESS_OF Patients
Subject
Negative
Predicate
PROCESS_OF
Object
Patients
9. cobicistat / darunavir TREATS Negative
Subject
cobicistat / darunavir
Predicate
TREATS
Object
Negative
10. cobicistat / darunavir TREATS Pneumonia caused by SARS-CoV-2
Subject
cobicistat / darunavir
Predicate
TREATS
Object
Pneumonia caused by SARS-CoV-2
11. Pneumonia caused by SARS-CoV-2 PROCESS_OF Patients
Subject
Pneumonia caused by SARS-CoV-2
Predicate
PROCESS_OF
Object
Patients
12. cobicistat / darunavir TREATS Patients
Subject
cobicistat / darunavir
Predicate
TREATS
Object
Patients
13. Cessation of life PROCESS_OF Patients
Subject
Cessation of life
Predicate
PROCESS_OF
Object
Patients
14. Drug Interactions PROCESS_OF Patients
Subject
Drug Interactions
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
The aim of this study was to evaluate both positive outcomes, including reduction of respiratory support aid and duration of hospital stay, and negative ones, including mortality and a composite of invasive mechanical ventilation or death, in patients with coronavirus disease 2019 (COVID-19) pneumonia treated with or without oral darunavir/cobicistat (DRV/c, 800/150 mg/day) used in different treatment durations. The secondary objective was to evaluate the percentage of patients treated with DRV/c who were exposed to potentially severe drug-drug interactions (DDIs) and died during hospitalization. This observational retrospective study was conducted in consecutive patients with COVID-19 pneumonia admitted to a tertiary care hospital in Modena, Italy. Kaplan-Meier survival curves and Cox proportional hazards regression were used to compare patients receiving standard of care with or without DRV/c. Adjustment for key confounders was applied. Two hundred seventy-three patients (115 on DRV/c) were included, 75.8% males, mean age was 64.6 (±13.2) years. Clinical improvement was similar between the groups, depicted by respiratory aid switch (p > .05). The same was observed for duration of hospital stay [13.2 (±8.9) for DRV/c vs. 13.4 (±7.2) days for no-DRV/c, p = .9]. Patients on DRV/c had higher rates of mortality (25.2% vs. 10.1%, p < .0001. The rate of composite outcome of mechanical ventilation and death was higher in the DRV/c group (37.4% vs. 25.3%, p = .03). Multiple serious DDI associated with DRV/c were observed in the 19 patients who died. DRV/c should not be recommended as a treatment option for COVID-19 pneumonia outside clinical trials.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-HIV Agents / Darunavir / Cobicistat / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: AIDS Res Hum Retroviruses Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article Affiliation country: Aid.2020.0305

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-HIV Agents / Darunavir / Cobicistat / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: AIDS Res Hum Retroviruses Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article Affiliation country: Aid.2020.0305